

Synthesis of Pentasaccharide Repeating Unit Corresponding to the Cell Wall O-Polysaccharide of *Salmonella enterica* O55 Strain Containing a Rare Sugar 3-Acetamido-3-deoxy-D-fucose

Arin Guichait


Monalisa Kundu

Anup Kumar Misra*

Division of Molecular Medicine, Bose Institute, P-1/12,

C.I.T. Scheme VII-M, Kolkata-700054, India

akmisra69@gmail.com



Received: 24.04.2021

Accepted after revision: 31.05.2021

Published online: 24.06.2021

DOI: 10.1055/s-0037-1610777; Art ID: ss-2021-g0237-op

Abstract A pentasaccharide repeating unit corresponding to the cell wall O-antigen of *Salmonella enterica* O55 containing a rare sugar, 3-acetamido-3-deoxy-D-fucose has been synthesized as its *p*-methoxyphenyl glycoside using a sequential stereoselective glycosylation strategy. A suitably functionalized 3-azido-3-deoxy-D-fucose thioglycoside derivative was prepared in very good yield and used in the stereoselective glycosylation reaction. Functionalized monosaccharide intermediates were prepared judiciously and stereoselectively assembled to get the desired pentasaccharide derivative in excellent yield.

Key words pentasaccharide, glycosylation, 3-acetamido-3-deoxy-D-fucose, *Salmonella enterica*, stereoselective

Food borne gastrointestinal disorders causing hospitalization and deaths are serious concern all over the world and particularly in the developing countries.^{1,2} Lack of adequate sanitization and intake of contaminated food and water are major cause of diarrheal infections.^{3,4} There are several pathogenic bacteria causing diarrheal outbreaks, which include *Escherichia coli* (*E. coli*),⁵ *Shigella*,⁶ *Vibrio cholerae*,⁷ *Proteus*,⁸ and *Salmonella*⁹ strains. The gastrointestinal disorders caused by the *Salmonella* infection are termed as salmonellosis,¹⁰ which are generally being treated with antimicrobial agents.¹¹ The causative agent of most of the occurrence of salmonellosis in humans and animals are *Salmonella enterica* (*S. enterica*) strains.¹² Most common symptoms of *Salmonella* infections are diarrhea, fever, vomiting with dehydration etc. Although a variety of therapeutics are being used for controlling food borne illness or diarrheal infections, they become ineffective because of the emergence of multidrug-resistant bacterial strains.¹³ As a result, there is a strong need to develop alternative approaches for controlling salmonellosis. In general, the polysaccharides present in the cell wall of the virulent bacteria

play the pivotal role in their pathogenicity and initial stage of infection to the host.¹⁴ Among several strains of *S. enterica*, responsible for diarrheal infections in humans, *S. enterica* O55 deserves special attention due to its unique cell wall polysaccharide structure containing a rare sugar, 3-amino-3-deoxy-D-fucose moiety. Liu et al.¹⁵ reported the structure of the pentasaccharide repeating unit of the cell wall polysaccharide of *S. enterica*, which is composed of five monosaccharide moieties namely, β -D-glucose, α -D-glucose, *N*-acetyl- α -D-galactosamine, *N*-acetyl- β -D-glucosamine, and β -3-acetamido-3-deoxy-D-fucose. In the past, polysaccharide-based glycoconjugates have emerged as effective vaccine candidates against several bacterial infections such as influenza,¹⁶ pneumococcal,¹⁷ and meningitis¹⁸ infections. Despite the possibility of obtaining the polysaccharides from bacterial sources using biofermentation techniques, it suffers from several drawbacks, such as heterogeneity of isolated polysaccharides, handling of live bacterial strains, difficult-to-remove biological impurities etc. In contrast, chemical synthesis of the polysaccharide fragments could provide homogeneous oligosaccharides with confirmed structures. In the recent past, a number of reports appeared from our laboratory towards the synthesis of cell wall oligosaccharides and their glycoconjugates of *Salmonella* strains.¹⁹ In continuation, a concise synthesis of the pentasaccharide repeating unit of the cell wall polysaccharide of *S. enterica* O55 is reported herein. The synthetic strategy involves the synthesis of a rare sugar derivative, i.e. 3-azido-3-deoxy- β -D-fucosyl thioglycoside **5** (Figure 1).

In order to synthesize the target pentasaccharide **1**, a sequential glycosylation strategy has been adopted. The suitably functionalized monosaccharide derivatives **2**,²⁰ **3**,²¹ **4**,²² **5**, and **6**²³ were prepared following the reaction conditions reported earlier. Thioglycoside derivatives **3**, **4**, **5**, and **6** were used as glycosyl donors for the elongation of the oligosaccharide chain under a generalized stereoselective glyco-




Figure 1 Structure of the synthesized pentasaccharide corresponding to the repeating unit of the cell wall polysaccharide of *Salmonella enterica* O55 strain


sylation condition in the presence of a combination^{19a,24} of *N*-iodosuccinimide (NIS) and perchloric acid supported over silica ($\text{HClO}_4\text{-SiO}_2$)²⁵ as thiophilic glycosylation activator.

Recently, $\text{HClO}_4\text{-SiO}_2$ has found applications in various types of organic transformations as a cheap, moisture stable, non-corrosive, solid protic acid equivalent.²⁶ Most of the conventionally used thiophilic activators²⁷ (e.g., triflic acid, TMSOTf, methyl triflate, DMTST) are moisture sensitive and corrosive in nature. Replacement of the corrosive and moisture sensitive acidic reagents by $\text{HClO}_4\text{-SiO}_2$ resulted satisfactory yields in stereoselective glycosylations.^{19a,24} Due to the simplicity of its preparation and compatibility with the glycosylation reactions and functional groups transformations in carbohydrates, $\text{HClO}_4\text{-SiO}_2$ in combination with NIS has been used in the present synthetic strategy for the activation of thioglycoside donors.

The rare sugar derivative **5**, was prepared from the *D*-fucose thioglycoside derivative using a multistep reaction sequence involving selective protection-deprotection of hydroxyl groups and double $\text{S}_{\text{N}}2$ inversion reactions.^{19a}

p-Methylphenyl 2-*O*-benzoyl-1-thio- β -*D*-fucopyranoside (**7**),²⁸ prepared from *D*-galactose in eight steps was subjected to a number of reactions involving: (a) selective *p*-methoxybenzylation at the C-3 hydroxyl group via the formation of stannylidene acetal using dibutyltin oxide followed by treatment with *p*-methoxybenzyl chloride (PMBCl) in the presence of tetrabutylammonium bromide (TBAB);²⁹ (b) benzylation of the C-4 hydroxyl group using benzyl bromide in the presence of sodium hydride;³⁰ and (c) oxidative removal of the PMB group using DDQ in a biphasic reaction condition³¹ to give *p*-methylphenyl

4-*O*-benzyl-2-*O*-benzoyl-1-thio- β -*D*-fucopyranoside (**8**) in 72% overall yield. Compound **8** was treated with triflic anhydride in the presence of pyridine to give the triflyl derivative, which was immediately treated with sodium nitrite³² to furnish corresponding *D*-gulose derivative, which on de-*O*-benzoylation using sodium methoxide resulted *p*-methylphenyl 4-*O*-benzyl-1-thio- β -*D*-gulopyranoside (**9**) in overall 58% yield. Selective protection of the 2-hydroxy group in compound **9** with the 2-naphthylmethyl (NAP) group via the formation of stannylidene acetal by the treatment with dibutyltin oxide followed by treatment of the stannylidene acetal with 2-naphthylmethyl bromide (NAP-Br) in the presence of cesium fluoride³³ furnished *p*-methylphenyl 4-*O*-benzyl-2-*O*-(2-naphthylmethyl)-1-thio- β -*D*-gulopyranoside (**10**) in 80% yield. Compound **10** was subjected to a sequence of functional group transformations which include: (i) treatment with triflic anhydride in the presence of pyridine to give the 3-*O*-triflyl derivative; (ii) $\text{S}_{\text{N}}2$ substitution of the 3-*O*-triflyl group with an azido group by treatment with sodium azide;³⁴ (iii) oxidative removal of the NAP group using DDQ in a biphasic reaction condition,³⁵ and finally (iv) acetylation of the free hydroxyl group to furnish *p*-methylphenyl 2-*O*-acetyl-3-azido-4-*O*-benzyl-3-deoxy-1-thio- β -*D*-fucopyranoside (**5**) in 65% overall yield (Scheme 1). All synthetic intermediates were characterized by their NMR and mass spectral analysis.




Scheme 1 Reagents and conditions: (a) (i) Bu_2SnO , CH_3OH , 80 °C, 3 h; (ii) PMBCl, TBAB, DMF, 65 °C, 6 h; (b) benzyl bromide, NaH, DMF, r.t., 2 h; (c) DDQ, $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ (10:1), r.t., 3 h, 72% (3 steps); (d) TiF_3O , pyridine, CH_2Cl_2 , -10 °C, 2 h; (e) NaNO_2 , DMF, 60 °C, 12 h; (f) 0.1 M CH_3ONa , CH_3OH , r.t., 3 h, 65% (3 steps); (g) (i) Bu_2SnO , CH_3OH , 80 °C, 3 h; (ii) 2-(bromomethyl)naphthalene (NAPBr), CsF, DMF, 65 °C, 6 h, 80%; (h) TiF_3O , pyridine, CH_2Cl_2 , -10 °C, 2 h; (i) NaN_3 , DMF, 60 °C, 12 h; (j) DDQ, $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ (10:1), r.t., 3 h; (k) Ac_2O , pyridine, r.t., 3 h, 65% (4 steps).

Having a set of suitably functionalized thioglycoside donors and acceptors in hand, attempts were made to couple monosaccharide derivatives by stereoselective glycosylations in the presence of a combination^{19a,24} of *N*-iodosuccinimide (NIS) and perchloric acid supported over silica ($\text{HClO}_4\text{-SiO}_2$)²⁵ as thiophilic activator. Stereoselective glycosylation of compound **2** with 2-azido-2-deoxy-*D*-galactose thioglycoside derivative **3** in the presence of a combination^{19a,24} of NIS and $\text{HClO}_4\text{-SiO}_2$ furnished disaccharide de-

rivative **11**, which on subsequent de-*O*-acetylation using sodium methoxide gave disaccharide acceptor **12** in 69% over all yield. NMR spectroscopic analysis of compound **12** confirmed its stereoselective formation [signals at $\delta = 5.74$ (d, $J = 8.5$ Hz, H-1_A), 5.64 (s, PhCH), 5.37 (d, $J = 3.5$ Hz, H-1_B) in ¹H NMR and $\delta = 101.5$ (PhCH), 98.6 (C-1_B), 98.2 (C-1_A) in ¹³C NMR spectra]. Although, the C-3 hydroxyl group is quite congested for the glycosylation reaction, the α -glycosidic linkage was formed in compound **12** with satisfactory yield without formation of the other stereoisomer. Stereoselective glycosylation of compound **12** with *D*-glucose derived thioglycoside donor **4** in the presence of a combination^{19a,24} of NIS and HClO₄-SiO₂ produced trisaccharide derivative **13**, which was immediately de-*O*-acetylated using sodium methoxide to furnish trisaccharide acceptor **14** in 73% yield. The formation of new glycosyl linkages in compound **14** was confirmed from its NMR spectroscopic analysis [signals at $\delta = 5.75$ (d, $J = 8.5$ Hz, H-1_A), 5.66 (s, PhCH), 5.42 (d, $J = 3.5$ Hz, H-1_B), 4.62 (br s, H-1_C) in ¹H NMR and $\delta = 101.7$ (PhCH), 99.4 (C-1_C), 98.8 (C-1_B), 98.1 (C-1_A) in ¹³C NMR spectra]. NIS and HClO₄-SiO₂ mediated^{19a,24} stereoselective glycosylation of trisaccharide **14** with 3-azido-3-deoxy-*D*-fucosyl thioglycoside derivative **5** furnished tetrasaccharide derivative **15** in 63% yield. NMR spectroscopic analysis of compound **15** confirmed its stereoselective formation [signals at $\delta = 5.67$ (d, $J = 8.0$ Hz, H-1_A), 5.58 (s, PhCH), 5.44 (d, $J = 3.0$ Hz, H-1_B), 4.67 (br s, H-1_C), 4.01 (d, $J = 8.0$ Hz, H-1_D) in ¹H NMR and $\delta = 101.6$ (PhCH), 100.2 (C-1_D), 99.4 (C-1_C), 99.0 (C-1_B), 98.2 (C-1_A) in ¹³C NMR spectra]. De-*O*-acetylation of compound **15** by treatment with sodium methoxide furnished tetrasaccharide acceptor **16** in 84% yield, which was characterized by its NMR spectral analysis. Compound **16** was allowed to couple stereoselectively with *D*-glucose thioglycoside derivative **6** in the presence of a combination^{19a,24} of NIS and HClO₄-SiO₂ to furnish pentasaccharide derivative **17** in 64% yield. The formation of new glycosyl linkages in compound **17** was confirmed from its NMR spectroscopic analysis [signals at $\delta = 5.52$ (d, $J = 8.0$ Hz, H-1_A), 4.95 (d, $J = 3.0$ Hz, H-1_B), 4.65 (d, $J = 3.0$ Hz, H-1_C), 4.00–3.98 (2 d, $J = 8.0$ Hz, H-1_D, H-1_E) in ¹H NMR and $\delta = 100.5$ (C-1_E), 100.4 (C-1_D), 99.4 (C-1_C), 98.9 (C-1_B), 98.1 (C-1_A) in ¹³C NMR spectra]. Compound **17** was subjected to a series of functional group transformations, which include (i) treatment with hydrazine hydrate monohydrate to remove phthaloyl group;³⁶ (ii) *N*- and *O*-acetylation using acetic anhydride and pyridine; (iii) transformation of the azido group into an acetamido group by treatment with thioacetic acid in pyridine;³⁷ (iv) de-*O*-acetylation using sodium methoxide; and finally (v) removal of benzyl ethers and benzylidene acetal by hydrogenolysis using hydrogen gas in the presence of Pearlman's catalyst³⁸ to give target pentasaccharide **1** as its *p*-methoxyphenyl glycoside in 52% over all yield. NMR spectroscopic analysis of compound **1** unambiguously supported its formation (signals at $\delta = 5.25$ (br s, H-1_C), 4.97 (br s, H-1_B), 4.95 (d, $J = 9.5$ Hz, H-1_A), 4.52 (d, $J = 9.0$ Hz, H-1_D), 4.32 (d, $J = 9.0$

Hz, 1 H, H-1_E) in ¹H NMR and $\delta = 102.8$ (C-1_D), 102.6 (C-1_E), 101.1 (C-1_A), 101.0 (C-1_B), 98.9 (C-1_C) in ¹³C NMR spectra] (Scheme 2).



In summary, a pentasaccharide repeating unit of the *O*-specific polysaccharide of *Salmonella enterica* O55 containing 3-acetamido-3-deoxy-*D*-fucose moiety has been synthesized in very good yield using a sequential glycosylations strategy. To the best of our knowledge, a suitably functionalized 3-azido-3-deoxy-*D*-fucose thioglycoside derivative was prepared in excellent yield and used in the stereoselective glycosylation reaction for the first time. A com-

bination of NIS and $\text{HClO}_4\text{-SiO}_2$ has been used as the thiophilic activator for the stereoselective glycosylations of thioglycosides in generalized reaction conditions. The yields of the glycosylation steps were very good with excellent stereo outcome.

All reactions were monitored by TLC over silica gel coated TLC plates. The spots on TLC were visualized by warming ceric sulfate (2% $\text{Ce}(\text{SO}_4)_2$ in 2 N H_2SO_4) sprayed plates on a hot plate. Silica gel 230–400 mesh was used for column chromatography. NMR spectra were recorded on Bruker Avance 500 MHz using CDCl_3 as solvent and TMS as internal reference unless stated otherwise. MS were recorded on a Bruker mass spectrometer. Optical rotations were recorded in a Jasco P-2000 spectrometer at 25 °C. Commercially available grades of organic solvents of adequate purity are used in all reactions. $\text{HClO}_4\text{-SiO}_2$ was prepared following the reported method.²⁵

p-Methylphenyl 4-O-Benzyl-2-O-benzoyl-1-thio-β-D-fucopyranoside (8)

To a solution of **7** (3 g, 8.02 mmol) in CH_3OH (45 mL) was added Bu_2SnO (2.4 g, 9.62 mmol) and the mixture was stirred at 80 °C for 3 h. The solvents were evaporated and co-evaporated with toluene (3 × 30 mL) under reduced pressure. To a solution of the crude product in dry DMF (20 mL) were added PMBCl (1.2 mL, 8.82 mmol) and TBAB (2.25 g) and the mixture was stirred at 65 °C for 6 h. The mixture was diluted with H_2O (100 mL) and extracted with EtOAc (100 mL). The organic layer was successively washed with 2 M HCl (50 mL) and H_2O (50 mL), dried (Na_2SO_4), and concentrated. To a solution of the crude product in DMF (20 mL) was added NaH (60% oil coated; 300 mg) and the mixture was stirred at 0 °C. To the stirred solution was added benzyl bromide (1.1 mL, 9.25 mmol) and the mixture was stirred at r.t. for 2 h. The mixture was quenched with aq NH_4Cl , diluted with H_2O (50 mL), and extracted with CH_2Cl_2 (100 mL). The organic layer was washed with H_2O (50 mL), dried (Na_2SO_4), and concentrated under reduced pressure. To a solution of the crude product in CH_2Cl_2 (27 mL) was added a solution of DDQ (1.3 g, 5.64 mmol) in H_2O (3 mL) and the biphasic mixture was stirred at r.t. for 3 h. The mixture was diluted with H_2O (50 mL) and extracted with CH_2Cl_2 (50 mL). The organic layer was washed with H_2O (50 mL), dried (Na_2SO_4), and concentrated. The obtained crude was purified by column chromatography (silica gel, hexane/ EtOAc 3:1) to give pure **8** (2.68 g, 72%) as a colorless oil.

$[\alpha]_D -7.0$ (c 1.0, CHCl_3).

^1H NMR (500 MHz, CDCl_3): δ = 7.99–6.96 (m, 14 H, Ar-H), 5.10 (t, J = 10.0 Hz, 1 H, H-2), 4.72 (br s, 2 H, CH_2Ph), 4.62 (d, J = 10.0 Hz, 1 H, H-1), 3.72 (m, 1 H, H-5), 3.61–3.58 (m, 2 H, H-3, H-4), 2.25 (s, 3 H, CH_3), 1.30 (d, J = 6.5 Hz, 3 H, CCH_3).

^{13}C NMR (125 MHz, CDCl_3): δ = 166.6 (COPh), 138.1–127.6 (Ar-C), 85.9 (C-1), 80.1 (C-3), 75.9 (CH_2Ph), 74.9 (C-5, C-4), 72.3 (C-2), 21.2 (CH_3), 17.2 (CCH_3).

HRMS (ESI): m/z $[M + H]^+$ calcd for $\text{C}_{27}\text{H}_{28}\text{O}_5\text{S}$ (464.1657): 465.1735; found: 465.1721.

p-Methylphenyl 4-O-Benzyl-1-thio-β-D-gulopyranoside (9)

A solution of compound **8** (1.8 g, 3.87 mmol) in dry CH_2Cl_2 (25 mL) was cooled to 10 °C. To the cooled reaction mixture were added pyridine (1 mL) and Tf_2O (715 μL , 4.26 mmol) and it was stirred at same temperature for 2 h. The solvents were removed and co-evaporated with toluene (2 × 20 mL) under reduced pressure. To a solution of the

crude product in dry DMF (10 mL) was added NaNO_2 (2 g, 29 mmol) and it was stirred at 60 °C for 12 h. The reaction mixture was diluted with H_2O (50 mL) and extracted with CH_2Cl_2 (50 mL). The organic layer was washed with water (50 mL), dried (Na_2SO_4) and concentrated. A solution of the crude product in 0.1 M CH_3ONa in CH_3OH (10 mL) was stirred at room temperature for 3 h, neutralized with Amberlite IR-120 (H+) resin, filtered and concentrated to give compound **9** (910 mg, 65%) as a colorless oil.

$[\alpha]_D -12.0$ (c 1.0, CHCl_3).

^1H NMR (500 MHz, CDCl_3): δ = 7.36–7.01 (m, 9 H, Ar-H), 4.71 (d, J = 10.0 Hz, 1 H, H-1), 4.59 (d, J = 12.0 Hz, 1 H, CH_2Ph), 4.48 (d, J = 12.0 Hz, 1 H, CH_2Ph), 4.14–4.13 (m, 1 H, H-5), 3.96–3.95 (m, 1 H, H-3), 3.67 (dd, J = 10.0, 3.5 Hz, 1 H, H-2), 3.30 (d, J = 2.5 Hz, 1 H, H-4), 2.27 (s, 3 H, CH_3), 1.19 (d, J = 6.5 Hz, 3 H, CCH_3).

^{13}C NMR (125 MHz, CDCl_3): δ = 138.0–126.9 (Ar-C), 86.0 (C-1), 78.0 (C-3), 72.8 (CH_2Ph), 71.7 (C-4), 67.5 (C-5), 66.9 (C-2), 21.2 (CH_3), 16.4 (CCH_3).

HRMS (ESI): m/z $[M + H]^+$ calcd for $\text{C}_{20}\text{H}_{24}\text{O}_4\text{S}$ (360.1395): 361.1473; found: 361.1460.

p-Methylphenyl 4-O-Benzyl-2-O-naphthylmethyl-1-thio-β-D-gulopyranoside (10)

To a solution of **9** (900 mg, 2.50 mmol) in CH_3OH (30 mL) was added Bu_2SnO (750 mg, 3.0 mmol) and the mixture was stirred at 80 °C for 3 h. The solvents were evaporated and co-evaporated with toluene (3 × 20 mL) under reduced pressure. To a solution of the crude product in dry DMF (10 mL) were added 2-(bromomethyl)naphthalene (610 mg, 2.75 mmol) and CsF (380 mg, 2.5 mmol) and the mixture was stirred at 65 °C for 6 h. The mixture was diluted with H_2O (50 mL) and extracted with EtOAc (50 mL). The organic layer was successively washed with 2 M HCl (50 mL) and H_2O (50 mL), dried (Na_2SO_4), and concentrated. The crude product was purified by column chromatography (silica gel, hexane/ EtOAc 2:1) to give pure **10** (1.0 g, 80%) as a colorless oil.

$[\alpha]_D -17.0$ (c 1.0, CHCl_3).

^1H NMR (500 MHz, CDCl_3): δ = 7.50–7.07 (m, 16 H, Ar-H), 4.95 (d, J = 10.0 Hz, 1 H, H-1), 4.89 (d, J = 10.0 Hz, 1 H, CH_2Ph), 4.68 (d, J = 11.5 Hz, 1 H, CH_2Ph), 4.44–4.43 (m, 2 H, CH_2Ph), 4.03–4.00 (m, 2 H, H-3, H-5), 3.76 (dd, J = 10.0, 3.0 Hz, 1 H, H-2), 3.35 (d, J = 2.5 Hz, 1 H, H-4), 2.37 (s, 3 H, CH_3), 1.27 (d, J = 6.5 Hz, 3 H, CCH_3).

^{13}C NMR (125 MHz, CDCl_3): δ = 132.2–125.9 (Ar-C), 83.9 (C-1), 78.0 (C-3), 73.7 (C-4), 73.1 (CH_2Ph), 72.9 (CH_2Ph), 71.1 (C-5), 67.1 (C-2), 21.2 (CH_3), 16.3 (CCH_3).

HRMS (ESI): m/z $[M + H]^+$ calcd for $\text{C}_{31}\text{H}_{32}\text{O}_4\text{S}$ (500.2021): 501.2099; found: 501.2082.

p-Methylphenyl 2-O-Acetyl-3-azido-4-O-benzyl-3-deoxy-1-thio-β-D-fucopyranoside (5)

A solution of **10** (1.0 g, 2.0 mmol) in dry CH_2Cl_2 (15 mL) was cooled to –10 °C. To the cooled mixture were added pyridine (0.5 mL) and Tf_2O (850 μL , 5.06 mmol) and it was stirred at –10 °C for 2 h. The solvents were removed and co-evaporated with toluene (2 × 20 mL) under reduced pressure. To a solution of the crude product in dry DMF (5 mL) was added NaN_3 (1.5 g, 23 mmol) and it was stirred at 60 °C for 12 h. The mixture was diluted with H_2O (50 mL) and extracted with CH_2Cl_2 (50 mL). The organic layer was washed with water (50 mL), dried (Na_2SO_4), and concentrated. To a solution of the crude product in CH_2Cl_2 (20 mL) was added a solution of DDQ (900 mg, 4.0 mmol) in H_2O (2 mL) and the biphasic mixture was stirred at r.t. for 3 h. The

mixture was diluted with H₂O (50 mL) and extracted with CH₂Cl₂ (50 mL). The organic layer was washed with H₂O (50 mL), dried (Na₂SO₄), and concentrated. To a solution of the crude product in pyridine (5 mL) was added Ac₂O (2 mL) and the mixture was stirred at r.t. for 3 h. The mixture was concentrated under reduced pressure and co-evaporated with toluene (3 × 20 mL). The crude product was purified by column chromatography (silica gel, hexane/EtOAc 3:1) to give pure **5** (555 mg, 65%) as a colorless oil.

[α]_D –10.0 (c 1.0, CHCl₃).

¹H NMR (500 MHz, CDCl₃): δ = 7.32–6.98 (m, 9 H, Ar-H), 5.23 (t, *J* = 5.0 Hz, 1 H, H-2), 4.85 (d, *J* = 11.5 Hz, 1 H, CH₂Ph), 4.53 (d, *J* = 11.5 Hz, 1 H, CH₂Ph), 4.47 (d, *J* = 10.0 Hz, 1 H, H-1), 3.54–3.47 (m, 2 H, H-4, H-5), 3.41 (dd, *J* = 10.5, 3.0 Hz, 1 H, H-3), 2.26 (s, 3 H, CH₃), 2.08 (s, 3 H, COCH₃), 1.17 (d, *J* = 6.5 Hz, 3 H, CCH₃).

¹³C NMR (125 MHz, CDCl₃): δ = 170.1 (COCH₃), 132.9–128.0 (Ar-C), 86.8 (C-1), 77.9 (C-3), 75.4 (CH₂Ph), 75.3 (C-4), 68.7 (C-5), 65.2 (C-2), 21.2 (CH₃), 20.9 (COCH₃), 17.0 (CCH₃).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₂H₂₅N₃O₄S (427.1566): 428.1644; found: 428.1656.

***p*-Methoxyphenyl (2-Azido-3,6-di-*O*-benzyl-2-deoxy- α -D-galactopyranosyl)-(1→3)-4,6-*O*-benzylidene-2-deoxy-2-*N*-phthalimido- β -D-glucopyranoside (12)**

To a solution of **2** (1.5 g, 2.98 mmol) and **3** (1.85 g, 3.57 mmol) in anhyd CH₂Cl₂ (10 mL) was added MS 4Å (1.5 g) and the mixture was cooled to –10 °C under argon. To the cooled mixture were added NIS (880 mg, 3.90 mmol) and HClO₄-SiO₂ (50 mg) and it was stirred at –10 °C for 2 h. The mixture was filtered through a Celite bed and washed with CH₂Cl₂ (50 mL). The combined organic layers were successively washed with 5% Na₂S₂O₃ (50 mL), sat. NaHCO₃ (50 mL), and H₂O (50 mL), dried (Na₂SO₄), passed through a short pad of silica gel, and concentrated. A solution of the disaccharide derivative in 0.01 M CH₃ONa in CH₃OH (30 mL) was stirred at r.t. for 1 h, neutralized with Amberlite IR-120 (H⁺) resin, filtered, and concentrated. The crude product was purified by column chromatography (silica gel, hexane/EtOAc 2:1) to give pure **12** (1.8 g, 69%) as a colorless oil.

[α]_D –23 (c 1.0, CHCl₃).

¹H NMR (500 MHz, CDCl₃): δ = 7.55–6.45 (m, 23 H, Ar-H), 5.74 (d, *J* = 8.5 Hz, 1 H, H-1_A), 5.64 (s, 1 H, PhCH), 5.37 (d, *J* = 3.5 Hz, 1 H, H-1_B), 4.80 (t, *J* = 9.0 Hz, 1 H, H-3_A), 4.69 (d, *J* = 11.5 Hz, 1 H, CH₂Ph), 4.64 (d, *J* = 11.5 Hz, 1 H, CH₂Ph), 4.57 (t, *J* = 8.5 Hz, 1 H, H-2_A), 4.41 (dd, *J* = 10.5, 5 Hz, 1 H, H-6_{AA}), 4.12 (d, *J* = 12.0 Hz, 1 H, CH₂Ph), 4.04 (d, *J* = 12.0 Hz, 1 H, CH₂Ph), 3.99 (t, *J* = 9.5 Hz, 1 H, H-4_A), 3.88 (t, *J* = 10.5 Hz, 1 H, H-6_{BA}), 3.82 (s, 1 H, H-4_B), 3.77 (dd, *J* = 10.5, 5.0 Hz, 1 H, H-3_B), 3.74–3.72 (m, 1 H, H-5_A), 3.70 (s, 3 H, OCH₃), 3.57 (dd, *J* = 11.0, 4.0 Hz, 1 H, H-2_B), 3.40 (t, *J* = 6.0 Hz, 1 H, H-5_B), 3.22 (t, *J* = 9.5, 2.0 Hz, 1 H, H-6_{AB}), 2.71 (dd, *J* = 10, 4.0 Hz, 1 H, H-6_{BB}).

¹³C NMR (125 MHz, CDCl₃): δ = 155.7–114.5 (Ar-C), 101.5 (PhCH), 98.6 (C-1_B), 98.2 (C-1_A), 82.3 (C-4_A), 75.4 (C-4_B), 74.4 (C-3_A), 73.1 (CH₂Ph), 72.0 (CH₂Ph), 68.9 (C-5_B), 68.6 (C-6_B), 68.4 (C-6_A), 66.1 (C-4_B), 66.0 (C-5_A), 58.6 (C-2_B), 55.4 (OCH₃), 55.1 (C-2_A).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₄₈H₄₆N₄O₁₂ (870.3112): 871.3190; found: 871.3177.

***p*-Methoxyphenyl (2,3,4-tri-*O*-Benzyl- α -D-glucopyranosyl)-(1→4)-(2-azido-3,6-di-*O*-benzyl-2-deoxy- α -D-galactopyranosyl)-(1→3)-4,6-*O*-benzylidene-2-deoxy-2-*N*-phthalimido- β -D-glucopyranoside (14)**

To a solution of **12** (1.1 g, 1.26 mmol) and **4** (900 mg, 1.51 mmol) in anhyd CH₂Cl₂ (10 mL) was added MS 4Å (1.0 g) and the mixture was cooled to –10 °C under argon. To the cooled mixture were added NIS (375 mg, 1.66 mmol) and HClO₄-SiO₂ (30 mg) and it was stirred at –10 °C for 2 h. The mixture was filtered through a Celite bed and washed with CH₂Cl₂ (50 mL). The combined organic layers were successively washed with 5% Na₂S₂O₃ (50 mL), sat. NaHCO₃ (50 mL), and H₂O (50 mL), dried (Na₂SO₄), passed through a short pad of silica gel, and concentrated. A solution of the trisaccharide derivative in 0.01 M CH₃ONa in CH₃OH (20 mL) was stirred at r.t. for 1 h, neutralized with Amberlite IR-120 (H⁺) resin, filtered, and concentrated. The crude product was purified by column chromatography (silica gel, hexane/EtOAc 3:1) to give pure **14** (1.2 g, 73%) as a colorless oil.

[α]_D –21.0 (c 1.0, CHCl₃).

¹H NMR (500 MHz, CDCl₃): δ = 7.74–6.69 (m, 38 H, Ar-H), 5.75 (d, *J* = 8.5 Hz, 1 H, H-1_A), 5.66 (s, 1 H, PhCH), 5.42 (d, *J* = 3.5 Hz, 1 H, H-1_B), 4.85–4.81 (m, 3 H, H-3_A, 2 CHPh), 4.80 (d, *J* = 11.5 Hz, 1 H, CHPh), 4.77 (d, *J* = 12.0 Hz, 1 H, CHPh), 4.71–4.63 (m, 2 H, 2 CHPh), 4.62 (br s, 1 H, H-1_C), 4.59–4.54 (m, 2 H, H-2_A, CHPh), 4.45–4.40 (m, 2 H, H-6_{AA}, CHPh), 4.00 (t, *J* = 9.0 Hz, 1 H, H-4_A), 3.91–3.83 (m, 3 H, H-3_C, H-5_C, H-6_{BA}), 3.83 (s, 1 H, H-4_B), 3.78–3.76 (m, 2 H, H-5_A, H-3_B), 3.70 (s, 3 H, OCH₃), 3.67 (d, *J* = 12.5 Hz, 1 H, CHPh), 3.62–3.60 (m, 2 H, H-2_B, H-6_{AB}), 3.55 (d, *J* = 12.0 Hz, 1 H, CHPh), 3.47–3.43 (m, 2 H, H-5_B, H-4_C), 3.29–3.27 (m, 2 H, H-2_C, H-6_{AC}), 3.20 (d, *J* = 10.0 Hz, 1 H, H-6_{BC}), 2.59–2.56 (m, 1 H, H-6_{BB}).

¹³C NMR (125 MHz, CDCl₃): δ = 155.7–114.5 (Ar-C), 101.7 (PhCH), 99.4 (C-1_C), 98.8 (C-1_B), 98.1 (C-1_A), 82.4 (C-4_A), 81.7 (C-3_C), 80.0 (C-2_C), 77.4 (C-4_C), 75.3 (CH₂Ph), 75.1 (C-4_B), 74.9 (CH₂Ph), 74.3 (C-3_A), 74.2 (C-4_B), 73.7 (CH₂Ph), 72.4 (CH₂Ph), 72.1 (CH₂Ph), 71.3 (C-5_C), 69.9 (C-5_B), 68.6 (C-6_A), 66.9 (C-6_B), 66.1 (C-5_A), 60.9 (C-6_C), 59.1 (C-2_B), 55.4 (OCH₃), 55.2 (C-2_A).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₇₅H₇₄N₄O₁₇ (1302.5049): 1303.5127; found: 1303.5118.

***p*-Methoxyphenyl (2-*O*-Acetyl-3-azido-4-*O*-benzyl-3-deoxy- β -D-fucopyranosyl)-(1→6)-(2,3,4-tri-*O*-benzyl- α -D-glucopyranosyl)-(1→4)-(2-azido-3,6-di-*O*-benzyl-2-deoxy- α -D-galactopyranosyl)-(1→3)-4,6-*O*-benzylidene-2-deoxy-2-*N*-phthalimido- β -D-glucopyranoside (15)**

To a solution of **14** (800 mg, 0.61 mmol) and **5** (395 mg, 0.91 mmol) in anhyd CH₂Cl₂ (10 mL) was added MS 4Å (0.5 g) and the mixture was cooled to –70 °C under argon. To the cooled mixture were added NIS (225 mg, 1.00 mmol) and HClO₄-SiO₂ (25 mg) and it was stirred at –70 °C for 3 h. The mixture was filtered through a Celite bed and washed with CH₂Cl₂ (50 mL). The combined organic layers were successively washed with 5% Na₂S₂O₃ (25 mL), sat. NaHCO₃ (25 mL), H₂O (25 mL), dried (Na₂SO₄), and concentrated. The crude product was purified by column chromatography (silica gel, hexane/EtOAc 3:1) to give pure **15** (620 mg, 63%) as a colorless oil.

[α]_D –19.0 (c 1.0, CHCl₃).

¹H NMR (500 MHz, CDCl₃): δ = 7.97–6.65 (m, 43 H, Ar-H), 5.67 (d, *J* = 8.0 Hz, 1 H, H-1_A), 5.58 (s, 1 H, PhCH), 5.44 (d, *J* = 3.0 Hz, 1 H, H-1_B), 5.16 (t, *J* = 8.0 Hz, 1 H, H-2_D), 4.84–4.68 (m, 6 H, 6 PhCH), 4.67 (br s, 1 H, H-1_C), 4.66–4.33 (m, 7 H, H-2_A, 6 PhCH), 4.01 (d, *J* = 8.0 Hz, 1 H, H-1_D), 3.96–3.90 (m, 2 H, H-3_C, H-6_{AA}), 3.88–3.76 (m, 3 H, H-3_B, H-3_D, H-4_C), 3.72–3.66 (m, 2 H, H-4_D, H-5_B), 3.64 (s, 3 H, OCH₃), 3.62–3.50 (m, 3

H, H-2_B, H-3_A, H-4_B), 3.49–3.32 (m, 5 H, H-4_A, H-5_C, H-6_{BA}, H-6_{BB}), 3.30–3.25 (m, 2 H, H-5_A, H-5_D), 3.20–3.11 (m, 2 H, H-2_C, H-6_{AC}), 2.52–2.48 (m, 1 H, H-6_{BC}), 1.74 (s, 3 H, COCH₃), 1.17 (s, 3 H, CCH₃).

¹³C NMR (125 MHz, CDCl₃): δ = 168.9 (COCH₃), 155.6–114.5 (Ar-C), 101.6 (PhCH), 100.2 (C-1_D), 99.4 (C-1_C), 99.0 (C-1_B), 98.2 (C-1_A), 82.4 (C-4_A), 81.8 (C-3_B), 80.1 (C-4_D), 79.6 (C-2_C), 77.5 (CH₂Ph), 75.1 (C-3_A), 74.9 (CH₂Ph), 74.6 (C-3_C), 74.5 (CH₂Ph), 74.4 (C-4_B), 74.0 (C-4_C), 73.9 (CH₂Ph), 73.8 (CH₂Ph), 72.2 (C-3_D), 72.1 (C-2_D), 72.0 (2C, 2 CH₂Ph), 69.8 (C-5_C), 69.7 (C-5_B), 69.6 (C-5_D), 68.6 (C-6_A), 67.0 (C-6_C), 66.8 (C-6_B), 66.1 (C-5_A), 58.9 (C-2_B), 55.5 (OCH₃), 55.2 (C-2_A), 20.8 (COCH₃), 17.4 (CCH₃).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₉₀H₉₁N₇O₂₁ (1605.6268): 1606.6346; found: 1606.6333.

p-Methoxyphenyl (3-Azido-4-O-benzyl-3-deoxy-β-D-fucopyranosyl)-(1→6)-(2,3,4-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-(2-azido-3,6-di-O-benzyl-2-deoxy-α-D-galactopyranosyl)-(1→3)-4,6-O-benzylidene-2-deoxy-2-N-phthalimido-β-D-glucopyranoside (16)

A solution of **15** (600 mg, 0.37 mmol) in 0.01 M CH₃ONa in CH₃OH (15 mL) was stirred at r.t. for 1 h, neutralized with Amberlite IR-120 (H⁺) resin, filtered, and concentrated. The crude product was purified by column chromatography (silica gel, hexane/EtOAc 2:1) to give pure **16** (486 g, 84%) as a colorless oil.

[α]_D –16.0 (c 1.0, CHCl₃).

¹H NMR (500 MHz, CDCl₃): δ = 7.66–6.61 (m, 43 H, Ar-H), 5.67 (d, *J* = 8.5 Hz, 1 H, H-1_A), 5.58 (s, 1 H, PhCH), 5.36 (d, *J* = 3.0 Hz, 1 H, H-1_B), 4.89 (t, *J* = 9.0 Hz, 1 H, H-2_A), 4.75–4.65 (m, 4 H, 4 CH₂Ph), 4.61–4.56 (m, 4 H, H-1_C, 3 CH₂Ph), 4.51–4.45 (m, 2 H, H-3_A, CH₂Ph), 4.40–4.34 (m, 3 H, H-6_{AA}, 2 CH₂Ph), 3.98–3.92 (m, 3 H, H-1_D, H-4_A, H-3_C), 3.80–3.77 (m, 3 H, H-6_{BA}, 2 CH₂Ph), 3.70–3.67 (m, 2 H, H-3_B, H-5_C), 3.63 (s, 3 H, OCH₃), 3.57–3.52 (m, 3 H, H-4_D, H-2_B, H-6_{AC}), 3.45–3.40 (m, 3 H, H-2_D, H-3_D, H-5_A), 3.34–3.20 (m, 5 H, H-2_C, H-4_C, H-5_B, H-4_B, H-6_{AB}), 3.12–3.10 (m, 2 H, H-5_D, H-6_{BB}), 2.49–2.45 (m, 1 H, H-6_{BC}), 1.21 (d, *J* = 6.5 Hz, 3 H, CCH₃).

¹³C NMR (125 MHz, CDCl₃): δ = 155.7–114.5 (Ar-C), 101.7 (PhCH), 100.4 (C-1_D), 99.4 (C-1_C), 98.9 (C-1_B), 98.1 (C-1_A), 83.1 (C-4_A), 82.4 (C-3_B), 81.8 (C-4_D), 79.8 (C-2_C), 77.7 (C-4_B), 75.1 (CH₂Ph), 74.9 (C-3_A), 74.6 (C-3_C), 74.5 (CH₂Ph), 74.4 (C-4_B), 74.0 (CH₂Ph), 73.9 (CH₂Ph), 73.8 (C-4_C), 72.2 (C-3_D), 72.1 (C-2_D), 72.0 (2 C, 2 CH₂Ph), 71.5 (C-5_C), 69.9 (C-5_B), 69.7 (C-5_D), 68.6 (C-6_A), 67.0 (C-6_C), 66.8 (C-6_B), 66.1 (C-5_A), 59.0 (C-2_B), 55.5 (OCH₃), 55.2 (C-2_A), 17.6 (CCH₃).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₈₈H₈₉N₇O₂₀ (1563.6162): 1564.6240; found: 1564.6228.

p-Methoxyphenyl (2,3,4-Tri-O-acetyl-6-O-benzyl-β-D-glucopyranosyl)-(1→2)-(3-azido-4-O-benzyl-3-deoxy-β-D-fucopyranosyl)-(1→6)-(2,3,4-tri-O-benzyl-α-D-glucopyranosyl)-(1→4)-(2-azido-3,6-di-O-benzyl-2-deoxy-α-D-galactopyranosyl)-(1→3)-4,6-O-benzylidene-2-deoxy-2-N-phthalimido-β-D-glucopyranoside (17)

To a solution of **16** (200 mg, 0.13 mmol) and **6** (130 mg, 0.26 mmol) in anhyd CH₂Cl₂ (5 mL) was added MS 4Å (0.3 g) and the mixture was cooled to –10 °C under argon. To the cooled mixture were added NIS (65 mg, 0.28 mmol) and HClO₄-SiO₂ (5 mg) and it was stirred at –20 °C for 3 h. The mixture was filtered through a Celite bed and washed with CH₂Cl₂ (20 mL). The combined organic layers were successively washed with 5% Na₂S₂O₃ (10 mL), sat. NaHCO₃ (10 mL), and H₂O (10 mL), dried (Na₂SO₄), and concentrated. The crude product was purified by column chromatography (silica gel, hexane/EtOAc 2:1) to give pure **17** (160 mg, 64%) as a colorless oil.

[α]_D –26.0 (c 1.0, CHCl₃).

¹H NMR (500 MHz, CDCl₃): δ = 7.27–6.61 (m, 48 H, Ar-H), 5.52 (d, *J* = 8.0 Hz, 1 H, H-1_A), 5.08 (t, *J* = 9.0 Hz, 1 H, H-3_A), 4.95 (d, *J* = 3.0 Hz, 1 H, H-1_B), 4.92–4.81 (m, 3 H, PhCH, H-3_E, CHPh), 4.82–4.65 (m, 6 H, 6 CHPh), 4.65 (d, *J* = 3.0 Hz, 1 H, H-1_C), 4.64–4.57 (m, 3 H, 3 CHPh), 4.53–4.42 (m, 5 H, 4 CH₂Ph, H-2_E), 4.40–4.30 (m, 2 H, H-2_A, H-4_E), 4.00–3.98 (2 d, *J* = 8.0 Hz, 2 H, H-1_D, H-1_E), 3.97–3.93 (m, 2 H, H-3_C, H-4_A), 3.90–3.82 (m, 2 H, H-3_B, H-5_C), 3.83–3.78 (m, 2 H, H-6_{AA}, H-3_D), 3.77–3.70 (m, 3 H, H-2_B, H-5_A, H-5_E), 3.65 (dd, *J* = 10.0, 3.0 Hz, 1 H, H-6_{BA}), 3.63 (s, 3 H, OCH₃), 3.52–3.33 (m, 8 H, H-2_C, H-4_B, H-4_D, H-5_B, H-6_{AB}, H-6_{BE}), 3.27 (t, *J* = 8.5 Hz, 1 H, H-2_D), 3.21 (t, *J* = 9.0 Hz, 1 H, H-4_C), 3.19–3.09 (m, 2 H, H-5_D, H-6_{AB}), 2.52–2.49 (m, 1 H, H-6_{BB}), 2.05 (s, 3 H, COCH₃), 2.0 (s, 3 H, COCH₃), 1.97 (s, 3 H, COCH₃), 1.07 (d, *J* = 6.5 Hz, 3 H, CCH₃).

¹³C NMR (125 MHz, CDCl₃): δ = 170.2 (COCH₃), 169.4 (COCH₃), 168.9 (COCH₃), 155.5–114.2 (Ar-C), 101.8 (PhCH), 100.5 (C-1_E), 100.4 (C-1_D), 99.4 (C-1_C), 98.9 (C-1_B), 98.1 (C-1_A), 83.1 (C-4_A), 83.0 (C-2_E), 82.4 (C-3_B), 81.8 (C-4_D), 80.8 (C-4_E), 79.8 (C-2_C), 77.7 (CH₂Ph), 75.1 (CH₂Ph), 74.9 (C-3_A), 74.6 (C-3_C), 74.5 (CH₂Ph), 74.4 (C-4_B), 74.0 (CH₂Ph), 73.9 (CH₂Ph), 73.8 (C-4_C), 73.3 (CH₂Ph), 72.2 (C-3_D), 72.1 (C-2_D), 72.0 (CH₂Ph), 71.5 (C-5_A), 70.9 (C-3_E), 70.2 (C-5_C), 69.9 (C-5_B), 69.7 (C-5_D), 69.6 (H-5_E), 66.6 (C-6_E), 66.9 (C-6_C), 66.8 (C-6_B), 66.1 (C-6_A), 59.0 (C-2_B), 55.5 (OCH₃), 55.2 (C-2_A), 20.9 (COCH₃), 20.7 (2 C, 2 COCH₃), 17.6 (CCH₃).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₁₀₇H₁₁₁N₇O₂₈ (1941.7477): 1942.7555; found: 1942.7540.

p-Methoxyphenyl (β-D-Glucopyranosyl)-(1→2)-(3-acetamido-3-deoxy-β-D-fucopyranosyl)-(1→6)-(α-D-glucopyranosyl)-(1→4)-(2-acetamido-2-deoxy-α-D-galactopyranosyl)-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranoside (1)

To a solution of **17** (100 mg, 0.05 mmol) in EtOH (10 mL) was added NH₂NH₂·H₂O (0.7 mL) and the mixture was stirred 80 °C for 12 h. The solvents were removed under reduced pressure and a solution of the crude product in Ac₂O (2 mL) and pyridine (2 mL) was kept at r.t. for 4 h. To a solution of the acetylated product in pyridine (2 mL) was added CH₃COSH (1.0 mL) and the mixture was stirred at r.t. for 12 h. The solvents were removed and co-evaporated with toluene (3 × 20 mL) under reduced pressure and the crude product was passed through a short pad of silica gel. A solution of the *N*-acetylated product in 0.1 M CH₃ONa in CH₃OH (10 mL) was stirred at r.t. for 6 h, neutralized with Amberlite IR-120 (H⁺) resin, filtered, and concentrated. To the solution of the de-*O*-acetylated product in CH₃OH (5 mL) was added 20% Pd(OH)₂-C (25 mg) and the mixture was stirred at r.t. under a positive pressure of H₂ for 24 h. The mixture was filtered through a Celite bed, washed with CH₃OH/H₂O (20 mL; 2:1), and concentrated under reduced pressure. The deprotected product was passed through a Sephadex LH-20 column (CH₃OH/H₂O 3:1) to give pure **1** (27 mg, 52%) as a white powder.

[α]_D –16.0 (c 0.5, H₂O).

¹H NMR (500 MHz, D₂O): δ = 7.20–6.91 (m, 4 H, Ar-H), 5.25 (br s, 1 H, H-1_C), 4.97 (br s, 1 H, H-1_B), 4.95 (d, *J* = 9.5 Hz, 1 H, H-1_A), 4.52 (d, *J* = 9.0 Hz, 1 H, H-1_D), 4.32 (d, *J* = 9.0 Hz, 1 H, H-1_E), 4.13–3.96 (m, 3 H, H-2_D, H-3_B, H-4_D), 3.95–3.86 (m, 2 H, H-6_{AA}, H-6_{AC}), 3.85–3.79 (m, 4 H, H-5_A, H-5_C, H-3_E, H-2_B), 3.71–3.65 (m, 9 H, H-6_{AB}, H-6_{BC}, H-6_{BA}, H-2_E, H-4_B, OCH₃), 3.64–3.59 (m, 5 H, H-2_C, H-3_A, H-3_D, H-4_C, H-6_{AB}), 3.53–3.50 (m, 2 H, H-5_D, H-6_{BB}), 3.45–3.40 (m, 3 H, H-2_A, H-3_C, H-4_E), 3.35–3.21 (m, 3 H, H-4_A, H-5_B, H-5_E), 2.05 (s, 3 H, NHCOCH₃), 1.97 (2 s, 6 H, 2 NHCOCH₃), 0.76 (d, *J* = 6.5 Hz, 3 H, CCH₃).

¹³C NMR (125 MHz, D₂O): δ = 170.2 (COCH₃), 169.4 (COCH₃), 168.9 (COCH₃), 154.7–115.4 (Ar-C), 102.8 (C-1_D), 102.6 (C-1_E), 101.1 (C-1_A), 101.0 (C-1_B), 98.9 (C-1_C), 79.0 (C-2_E), 77.6 (C-4_B), 76.1 (C-3_E), 75.0 (C-

5_E), 74.6 (C-5_A), 74.0 (C-2_D), 73.5 (C-2_C), 73.0 (2 C, C-5_C, C-5_D), 72.6 (2 C, C-3_C, C-5_B), 72.0 (3 C, C-3_A, C-4_C, C-4_D), 71.6 (C-4_E), 71.1 (C-4_A), 69.6 (C-3_B), 68.1 (C-6_C), 67.5 (C-3_D), 62.8 (C-6_A), 60.9 (C-6_E), 59.9 (C-6_B), 56.1 (OCH₃), 55.5 (C-2_A), 50.8 (C-2_B), 22.5 (NHCOCH₃), 20.8 (NHCOCH₃), 20.4 (NHCOCH₃), 16.8 (CCH₃).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₄₃H₆₇N₃O₂₆ (1041.4013): 1042.4091; found: 1042.4077.

Conflict of Interest

The authors declare no conflict of interest.

Funding Information

A.G. and M.K. thank Council of Scientific and Industrial Research, New Delhi, India (CSIR) for providing senior research fellowships. This work was supported by Science and Engineering Research Board (SERB), New Delhi (Project No. CRG/2019/000352 dated 23.01.2020) (A.K.M.).

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0037-1610777>. Copies of 1D and 2D NMR spectra of compounds **1** and **8–17** are provided.

References

- (1) (a) Mandeville, K. L.; Krabshuis, J.; Ladep, N. G.; Mulder, C. J. J.; Quigley, E. M. M.; Khan, S. A. *World J. Gastroenterol.* **2009**, *15*, 2839. (b) Milivojevic, V.; Milosavljevic, T. *Curr. Treat. Options Gastroenterol.* **2020**, *18*, 148. (c) Dumic, I.; Nordin, T.; Jecmenica, M.; Lalosevic, M. S.; Milosavljevic, T.; Milovanovic, T. *Can. J. Gastroenterol. Hepatol.* **2019**, *2019*, 6757524, DOI: 10.1155/2019/6757524.
- (2) (a) Fletcher, S. M.; McLaws, M.-L.; Ellis, J. T. *J. Public Health Res.* **2013**, *2*, 42. (b) Williams, J.; Roberts, S.; Ali, F.; Cheung, W.; Cohen, D.; Demery, G.; Edwards, A.; Greer, M.; Hellier, M.; Hutchings, H.; Ip, B.; Longo, M.; Russell, I.; Snooks, H.; Williams, J. *Gut* **2007**, *56*, 01 : 1. (c) Guerrant, R. L.; Hughes, J. M.; Lima, N. L.; Crane, J. *Rev. Infect. Dis.* **1990**, *12*, S41.
- (3) (a) Oloruntoba, E. O.; Folarin, T. B.; Idowu-Ayede, A. *Afr. Health Sci.* **2014**, *14*, 1001. (b) Huttly, S. R.; Morris, S. S.; Pisani, V. *Bull. W. H. O.* **1997**, *75*, 163. (c) Florez, I. D.; Niño-Serna, L. F.; Beltrán-Arroyave, C. P. *Curr. Infect. Dis. Rep.* **2020**, *22*, 4 DOI: 10.1007/s11908-020-0713-6.
- (4) (a) Casburnn-Jones, A. C.; Farthing, M. J. *Gut* **2004**, *53*, 296. (b) Lima, A. A.; Guerrant, R. L. *Epidemiol. Rev.* **1992**, *14*, 222. (c) Niyogi, S. K.; Saha, M. R.; De, S. P. *Indian J. Public Health* **1994**, *38*, 29. (d) Shankar, P.; Mishra, J.; Bharti, V.; Parashar, D.; Singh, S. *J. Lab. Physicians* **2019**, *11*, 275.
- (5) (a) Beatty, M. E.; Adcock, P. M.; Smith, S. W.; Quinlan, K.; Kamimoto, L. A.; Rowe, S. Y.; Scott, K.; Conover, C.; Varchmin, T.; Bopp, C. A.; Greene, K. D.; Bibb, B.; Slutsker, L.; Mintz, E. D. *Clin. Infect. Dis.* **2006**, *42*, 329. (b) Gomes, T. A. T.; Elias, W. P.; Scaletsky, I. C. A.; Guth, B. E. C.; Rodrigues, J. F.; Piazza, R. M. F.; Ferreira, L. C. S.; Martinez, M. B. *Braz. J. Microbiol.* **2016**, *47*, 3.
- (6) Baker, S.; The, H. C. *Curr. Opin. Infect. Dis.* **2018**, *31*, 449.
- (7) Davies, H. G.; Bowman, C.; Luby, S. P. *J. Infect.* **2017**, *74*, 01 : S66.
- (8) Hamilton, A. L.; Kamm, M. A.; Ng, S. C.; Morrison, M. *Clin. Microbiol. Rev.* **2018**, *31*, e00085 DOI: 10.1128/CMR.00085-17.
- (9) (a) Aljoudi, A. S.; Al-Mazam, A.; Choudhry, A. J. *J. Family Community Med.* **2010**, *17*, 29. (b) Lu, X.; Zeng, M.; Xu, J.; Zhou, H.; Gu, B.; Li, Z.; Jin, H.; Wang, X.; Zhang, W.; Hu, Y.; Xiao, W.; Zhu, B.; Xu, X.; Kan, B. *EbioMedicine* **2019**, *42*, 133.
- (10) (a) Crum-Cianflone, N. F. *Curr. Gastroenterol. Rep.* **2008**, *10*, 424. (b) Zha, L.; Garrett, S.; Sun, J. *Diseases* **2019**, *7*, 28 DOI: 10.3390/diseases7010028.
- (11) (a) Stoycheva, M. V.; Murdjeva, M. A. *Folia Med. (Sofia, Bulg.)* **2006**, *48*, 5. (b) Ray, K. A.; Warnick, L. D.; Mitchell, R. M.; Kaneene, J. B.; Ruegg, P. L.; Wells, S. J.; Fossler, C. P.; Halberd, L. W.; May, K. J. *Dairy Sci.* **2006**, *89*, 2038. (c) Mu, H.; Bai, H.; Sun, F.; Liu, Y.; Lu, C.; Qiu, Y.; Chen, P.; Yang, Y.; Kong, L.; Duan, J. *Nat. Commun.* **2019**, *10*, 4039. (d) Hirose, K.; Tamura, K.; Sagara, H.; Watanabe, H. *Antimicrob. Agents Chemother.* **2001**, *45*, 956.
- (12) (a) Jajere, S. M. *Vet. World* **2019**, *12*, 504. (b) Eng, S.-K.; Pusparajah, P.; Ab Mutalib, N.-S.; Ser, H.-L.; Chan, K.-G.; Lee, L.-H. *Front. Life Sci.* **2015**, *8*, 284.
- (13) (a) Fair, R. J.; Tor, Y. *Perspect. Med. Chem.* **2014**, *6*, 25. (b) Appelbaum, P. C. *J. Antimicrob. Chemother.* **2012**, *67*, 2062. (c) Sipahi, O. R. *Expert Rev. Anti-Infect. Ther.* **2008**, *6*, 523.
- (14) (a) Moxon, E. R.; Kroll, J. S. *Curr. Top. Microbiol. Immunol.* **1990**, *150*, 65. (b) Taylor, C. M.; Roberts, I. S. *Contrib. Microbiol.* **2005**, *12*, 55.
- (15) Liu, B.; Perepelov, A. V.; Svensson, M. V.; Shevelev, S. D.; Guo, D.; Senchenkova, S. N.; Shashkov, A. S.; Weintraub, A.; Feng, L.; Widmalm, G.; Knirel, Y. A.; Wang, L. *Glycobiology* **2010**, *20*, 679.
- (16) Gilchrist, S. A. N.; Nanni, A.; Levine, O. *Am. J. Public Health* **2012**, *102*, 596.
- (17) (a) Thindwa, D.; Quesada, M. G.; Liu, Y.; Bennett, J.; Cohen, C.; Knoll, M. D.; von Gottberg, A.; Hayford, K.; Flasche, S. *Vaccine* **2020**, *38*, 5398. (b) Nichol, K. L. *Vaccine* **1999**, *17*, S91.
- (18) (a) Pace, D.; Pollard, A. J. *Arch. Dis. Child.* **2007**, *92*, 909. (b) Poland, G. A. *Clin. Infect. Dis.* **2010**, *50*, S45.
- (19) (a) Gucchait, A.; Shit, P.; Misra, A. K. *Tetrahedron* **2020**, *76*, 131412. (b) Dhara, D.; Baliban, S. M.; Huo, C. X.; Rashidijahanabad, Z.; Sears, K. T.; Nick, S. T.; Misra, A. K.; Tennant, S. M.; Huang, X. *Chem. Eur. J.* **2020**, *26*, 15953. (c) Huo, C.-X.; Dhara, D.; Baliban, S. M.; Nick, S. T.; Tan, Z.; Simon, S.; Misra, A. K.; Huang, X. *Chem. Commun.* **2019**, *55*, 4519. (d) Bhaumik, I.; Misra, A. K. *ChemistrySelect* **2017**, *2*, 3065. (e) Bhaumik, I.; Misra, A. K. *ChemistrySelect* **2017**, *2*, 937. (f) Dhara, D.; Misra, A. K. *ChemistryOpen* **2015**, *4*, 768. (g) Dhara, D.; Mandal, P. K.; Misra, A. K. *Tetrahedron: Asymmetry* **2014**, *25*, 263. (h) Ghosh, T.; Santra, A.; Misra, A. K. *Tetrahedron: Asymmetry* **2013**, *24*, 606. (i) Sau, A.; Panchadhayee, R.; Ghosh, D.; Misra, A. K. *Carbohydr. Res.* **2012**, *352*, 18.
- (20) Nicolaou, K. C.; Bockovich, N. J.; Carcanague, D. R.; Hummel, C. W.; Even, L. F. *J. Am. Chem. Soc.* **1992**, *114*, 8701.
- (21) Kalikanda, J.; Li, Z. *J. Org. Chem.* **2011**, *76*, 5207.
- (22) Hsu, Y.; Lu, X.-A.; Zulueta, M. L.; Tsai, C.-M.; Lin, K.-I.; Hung, S.-C.; Wong, C.-H. *J. Am. Chem. Soc.* **2012**, *134*, 4549.
- (23) Huang, T.-Y.; Zulueta, M. M. L.; Hung, S.-C. *Org. Biomol. Chem.* **2014**, *12*, 376.
- (24) (a) Mukherjee, C.; Misra, A. K. *Synthesis* **2007**, 683. (b) Manna, T.; Gucchait, A.; Misra, A. K. *Beilstein J. Org. Chem.* **2020**, *16*, 106. (c) Shit, P.; Misra, A. K. *Glycoconjugate J.* **2020**, *37*, 647. (d) Kundu, M.; Gucchait, A.; Misra, A. K. *Tetrahedron* **2020**, *76*, 130952. (e) Manna, T.; Misra, A. K. *Carbohydr. Res.* **2021**, *502*, 108294. (f) Kundu, M.; Misra, A. K. *Carbohydr. Res.* **2019**, *486*, 107830. (g) Shit, P.; Gucchait, A.; Misra, A. K. *Tetrahedron* **2019**, *75*, 130697.

- (25) Chakraborti, A. K.; Gulhane, R. *Chem. Commun.* **2003**, 1896.
- (26) (a) Khatik, G. L.; Sharma, G.; Kumar, R.; Chakraborti, A. K. *Tetrahedron* **2007**, *63*, 1200. (b) Kumar, D.; Kommi, D. N.; Chebolu, R.; Garg, S. K.; Kumar, R.; Chakraborti, A. K. *RSC Adv.* **2013**, *3*, 91. (c) Kumar, D.; Sonawane, M.; Pujala, B.; Jain, V. K.; Bhagat, S.; Chakraborti, A. K. *Green Chem.* **2013**, *15*, 2872. (d) Rudrawar, S.; Besra, R. C.; Chakraborti, A. K. *Synthesis* **2006**, 2767. (e) Kumar, R.; Kumar, D.; Chakraborti, A. K. *Synthesis* **2007**, 299. (f) Chakraborti, A. K.; Sunay, V.; Chankeshwara, S. V. *Org. Biomol. Chem.* **2006**, *4*, 2769. (g) Agarwal, A.; Rani, S.; Vankar, Y. D. *J. Org. Chem.* **2004**, *69*, 6137. (h) Misra, A. K.; Tiwari, P.; Madhusudan, S. K. *Carbohydr. Res.* **2005**, *340*, 325. (i) Misra, A. K.; Tiwari, P.; Agnihotri, G. *Synthesis* **2005**, 260. (j) Khan, A. T.; Choudhury, L. H.; Ghosh, S. *J. Mol. Catal. A: Chem.* **2006**, 255, 230. (k) Ansari, M. I.; Hussain, M. K.; Yadav, N.; Gupta, P. K.; Hajela, K. *Tetrahedron Lett.* **2012**, *53*, 2063.
- (27) (a) Das, R.; Mukhopadhyay, B. *ChemistryOpen* **2016**, *5*, 401. (b) Lian, G.; Zhang, X.; Yu, B. *Carbohydr. Res.* **2015**, *403*, 13. (c) Codée, J. D. C.; Litjens, R. E. J. N.; van den Bos, L. J.; Overkleef, H. S.; van der Marel, G. A. *Chem. Soc. Rev.* **2005**, *34*, 769.
- (28) Adak, A.; Mukhopadhyay, B. *Carbohydr. Res.* **2019**, *476*, 1.
- (29) Kiyoi, T.; Nakai, Y.; Kondo, H.; Ishida, H.; Kiso, M.; Hasegawa, A. *Bioorg. Med. Chem.* **1996**, *4*, 1167.
- (30) Brimacombe, J. S. *Methods Carbohydr. Chem.* **1972**, *6*, 376.
- (31) Wuts, P. G. M. In *Handbook of Reagents for Organic Synthesis: Reagents for Glycoside, Nucleotide, and Peptide Synthesis*; Crich, D., Ed.; Wiley: Chichester, **2005**, 425.
- (32) Dong, H.; Rahm, M.; Thota, N.; Deng, L.; Brinck, T.; Ramström, O. *Org. Biomol. Chem.* **2013**, *11*, 648.
- (33) Augé, C.; David, S.; Veyrières, A. *J. Chem. Soc., Chem. Commun.* **1976**, 375.
- (34) Dhakal, B.; Bohé, L.; Crich, D. *J. Org. Chem.* **2017**, *82*, 9263.
- (35) Lloyd, D.; Bylsma, M.; Bright, D. K.; Chen, X.; Bennett, C. S. *J. Org. Chem.* **2017**, *82*, 3926.
- (36) Lee, H.-H.; Schwartz, D. A.; Harris, J. F.; Carver, J. P.; Krepinsky, J. *J. Can. J. Chem.* **1986**, *64*, 1912.
- (37) Shangguan, N.; Katukojvala, S.; Greenberg, R.; Williams, L. J. *J. Am. Chem. Soc.* **2003**, *125*, 7754.
- (38) Pearlman, W. M. *Tetrahedron Lett.* **1967**, *8*, 1663.